Ad
related to: nupercainal cream by novartis phone number
Search results
Results From The WOW.Com Content Network
Pimecrolimus was developed by Novartis. Its development number was ascomycin derivative ASM 981. [22] The New Drug Application (NDA) was filed December 15, 2000. It received US FDA approval on December 13, 2001. [23] At its US approval, it was one of the first new eczema treatments introduced since the topical corticosteroids of the 1950s. [24]
Cinchocaine (INN/BAN) or dibucaine is an amide local anesthetic.Among the most potent and toxic of the long-acting local anesthetics, current use of cinchocaine is generally restricted to spinal and topical anesthesia.
Pages in category "Drugs developed by Novartis" The following 135 pages are in this category, out of 135 total. ... Contact Wikipedia; Code of Conduct; Developers ...
Chiron Corporation (/ ˈ k aɪ r ɒ n / KY-ron) [1] was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006.
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. . Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary ...
[16] 2013 saw the company complete its highest number of acquisitions with Lotus Tissue Repair, Inc. (lead compound, ABH001), [17] SARcode Bioscience Inc., [18] with the last being ViroPharma. Shire changed the name of ViroPharma to Shire Viropharma Inc. upon acquisition and on their final day of trading the company was valued at $3.3 billion. [19]